No abstract available.
Congenital Abnormalities* ; Hypertrophy*

No abstract available.
Congenital Hypothyroidism*

OBJECTIVE: This study was performed to find out mitochondrial deoxyribonucleic acid mutations in preeclampsia because Mendelian models fail to explain all the patterns of inheritance in preeclampsia. METHODS: Ten preeclampsia patients and two of their related family members who have the obstetric history of preeclampsia were studied. The mitochondrial transfer ribonucleic acidleu[UUR] gene was amplified using polymerase chain reaction, cut by a restriction endonuclease (Apa , and also sequenced to see the whole gene. RESULTS: There were neither the known mutation at Nucleotide 3243 nor other mutations on the mitochondrial transfer ribonucleic acidleu[UUR] gene in these objects. CONCLUSION: It seems that the known mutation of mitochondrial transfer ribonucleic acidleu[UUR] gene is not so frequently detected in preeclampsia of South Korean, But it could not be concluded how many South Korean women with preeclampsia have the mutation.
DNA ; DNA Restriction Enzymes ; Female ; Humans ; Point Mutation* ; Polymerase Chain Reaction ; Pre-Eclampsia* ; RNA* ; Wills

No abstract available.
Congenital Abnormalities* ; Ear Cartilage* ; Ear* ; Sutures*

No abstract available.
Mandibulofacial Dysostosis*

No abstract available.
Cryotherapy* ; Nevus*

No abstract available.
Asthma*

No abstract available.
Female ; Pregnancy ; Pregnancy, Ectopic*

BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) is hardly controllable organism among the pathogen of nosocomial infection, because it is resistant to most antibiotics except vancomycin and local treatment with most antiseptics are not effective to eradicate MRSA from the infected wounds. There is increasing fear that MRSA infection can be spread widely in the hospitals. The effectiveness of Gentian Violet against MRSA was reported by Saji et al in 1992 for the first time. We tried Gentian Violet dressing on MRSA infected wounds to evaluate whether at not the Gentian Violet is effective to eradicate 11RSA which existed in the open wound. METHODS: 24 patients were treated by wet dressing with 0.1%Gentian Violet soaked gauze twice daily. They included 10 cases of sacral and trochanteric pressure sore, 6 cases of postoperative wound infectious, 3 cases of posttraumatic skin defects, 2 cases of DM foot, 1 case of post infectious skin defect and 2 cases of electrical burn, The wound culture was evaluated for elimination of MRSA infection twice weekly. RESULTS: The clinical results revealed that MRSA was not detected in all cases within 34days (average 13.5 days) after topical administration 0.1% Gentian Violet. CONCLUSION: There is no evidence of tissue irritation with Gentian Violet dressing on open wound or wound margin. After negative conversion of MRSA with Gentian Violet dressing, gram (-) organism was isolated in a half of the cases. 0.1% Gentian Violet topical administration is a useful treatment method of wound infection with MRSA.
Administration, Topical ; Anti-Bacterial Agents ; Anti-Infective Agents, Local ; Bandages* ; Burns ; Cross Infection ; Femur ; Foot ; Gentian Violet* ; Gentiana* ; Humans ; Methicillin-Resistant Staphylococcus aureus* ; Pressure Ulcer ; Skin ; Vancomycin ; Viola ; Wound Infection* ; Wounds and Injuries*

No abstract available.
Aged ; Humans